Natco Board Approves Proposal to Acquire U.S. Pharmaceutical Company
Natco Pharma announced on Tuesday that its board of directors had approved a proposed acquisition of US-based Dash Pharmaceuticals LLC for cash consideration of $18 million.
The company’s board of directors has approved the acquisition of Dash Pharmaceuticals through one of its subsidiaries, the drugmaker said in a regulatory filing.
Natco, through its affiliates, is offering to enter into an agreement to acquire Dash Pharmaceuticals subject to the satisfactory completion of due diligence, execution of definitive agreements and compliance with legal requirements, it said. he adds.
Dash is a pharmaceutical sales, marketing and distribution entity based in New Jersey, United States, which is expected to have net sales of approximately $15 million for the year ending December 2021.
This acquisition will provide the company with a front-end to engage directly with its customers in the United States, which is the world’s largest pharmaceutical market, Natco Pharma noted.
(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)